Cargando…

Calprotectin instability may lead to undertreatment in children with IBD

BACKGROUND: Treatment decisions in children with inflammatory bowel disease (IBD) are increasingly based on longitudinal tracking of faecal calprotectin concentrations, but there is little known about the stability of this protein in stool. METHODS: We stored aliquots of homogenised stool at room te...

Descripción completa

Detalles Bibliográficos
Autores principales: Haisma, Sjoukje-Marije, van Rheenen, Patrick Ferry, Wagenmakers, Lucie, Muller Kobold, Anneke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513246/
https://www.ncbi.nlm.nih.gov/pubmed/30655264
http://dx.doi.org/10.1136/archdischild-2018-316584
_version_ 1783586343859781632
author Haisma, Sjoukje-Marije
van Rheenen, Patrick Ferry
Wagenmakers, Lucie
Muller Kobold, Anneke
author_facet Haisma, Sjoukje-Marije
van Rheenen, Patrick Ferry
Wagenmakers, Lucie
Muller Kobold, Anneke
author_sort Haisma, Sjoukje-Marije
collection PubMed
description BACKGROUND: Treatment decisions in children with inflammatory bowel disease (IBD) are increasingly based on longitudinal tracking of faecal calprotectin concentrations, but there is little known about the stability of this protein in stool. METHODS: We stored aliquots of homogenised stool at room temperature and at 4°C, and measured the calprotectin concentration for 6 consecutive days with three different assays. In addition, we assessed calprotectin stability in assay-specific extraction buffers kept at room temperature. RESULTS: After 6 days of storage at room temperature, mean percentage change from baseline calprotectin concentrations in stool and extraction buffer was 35% and 46%, respectively. The stability of calprotectin was significantly better preserved in samples stored at 4°C (p=0.0066 and 0.0011, respectively). CONCLUSIONS: Calprotectin is not stable at room temperature. Children with IBD and their caretakers may be falsely reassured by low calprotectin values. The best advisable standard for preanalytical calprotectin handling is refrigeration of the stool sample until delivery at the hospital laboratory.
format Online
Article
Text
id pubmed-7513246
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-75132462020-10-05 Calprotectin instability may lead to undertreatment in children with IBD Haisma, Sjoukje-Marije van Rheenen, Patrick Ferry Wagenmakers, Lucie Muller Kobold, Anneke Arch Dis Child Short Report BACKGROUND: Treatment decisions in children with inflammatory bowel disease (IBD) are increasingly based on longitudinal tracking of faecal calprotectin concentrations, but there is little known about the stability of this protein in stool. METHODS: We stored aliquots of homogenised stool at room temperature and at 4°C, and measured the calprotectin concentration for 6 consecutive days with three different assays. In addition, we assessed calprotectin stability in assay-specific extraction buffers kept at room temperature. RESULTS: After 6 days of storage at room temperature, mean percentage change from baseline calprotectin concentrations in stool and extraction buffer was 35% and 46%, respectively. The stability of calprotectin was significantly better preserved in samples stored at 4°C (p=0.0066 and 0.0011, respectively). CONCLUSIONS: Calprotectin is not stable at room temperature. Children with IBD and their caretakers may be falsely reassured by low calprotectin values. The best advisable standard for preanalytical calprotectin handling is refrigeration of the stool sample until delivery at the hospital laboratory. BMJ Publishing Group 2020-10 2019-01-17 /pmc/articles/PMC7513246/ /pubmed/30655264 http://dx.doi.org/10.1136/archdischild-2018-316584 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Short Report
Haisma, Sjoukje-Marije
van Rheenen, Patrick Ferry
Wagenmakers, Lucie
Muller Kobold, Anneke
Calprotectin instability may lead to undertreatment in children with IBD
title Calprotectin instability may lead to undertreatment in children with IBD
title_full Calprotectin instability may lead to undertreatment in children with IBD
title_fullStr Calprotectin instability may lead to undertreatment in children with IBD
title_full_unstemmed Calprotectin instability may lead to undertreatment in children with IBD
title_short Calprotectin instability may lead to undertreatment in children with IBD
title_sort calprotectin instability may lead to undertreatment in children with ibd
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513246/
https://www.ncbi.nlm.nih.gov/pubmed/30655264
http://dx.doi.org/10.1136/archdischild-2018-316584
work_keys_str_mv AT haismasjoukjemarije calprotectininstabilitymayleadtoundertreatmentinchildrenwithibd
AT vanrheenenpatrickferry calprotectininstabilitymayleadtoundertreatmentinchildrenwithibd
AT wagenmakerslucie calprotectininstabilitymayleadtoundertreatmentinchildrenwithibd
AT mullerkoboldanneke calprotectininstabilitymayleadtoundertreatmentinchildrenwithibd